Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.
A trial looking at standard or high dose treatment for people recently diagnosed with non Hodgkin lymphoma (MISTRAL)
This trial compared standard treatment with high dose treatment for people newly diagnosed with non Hodgkin lymphoma. It recruited people who had a moderate or high risk of their lymphoma coming back after treatment. This trial was supported by Cancer Research UK.
Doctors usually treat high grade non Hodgkin lymphoma with a combination of chemotherapy drugs called CHOP. But doctors wanted to find out if giving more intensive treatment might work better than standard treatment.
The high dose chemotherapy regimen in this trial included one cycle of CHOP followed by 3 chemotherapy drugs called cyclophosphamide, methotrexate and etoposide. The final phase of treatment is with 2 other chemotherapy drugs called mitoxantrone and melphalan, followed by a stem cell transplant.
The aims of the trial were to compare standard CHOP chemotherapy with high dose treatment to see which is better at treating newly diagnosed non Hodgkin lymphoma. And to find out more about the side effects.
Summary of results
The researchers found that the high dose chemotherapy used in this trial was not a useful treatment for newly diagnosed non Hodgkin lymphoma that has a higher risk of coming back.
This trial recruited 136 people with non Hodgkin lymphoma who had not had treatment for their cancer before.
- Half had between 6 and 8 cycles of CHOP
- Half had high dose chemotherapy (which included CHOP) followed by a stem cell transplant
In 2003, the researchers did an early analysis of the results they had so far. They looked at how many people were alive for 2 years after treatment and at the side effects. Based on the findings of this, an independent group of doctors and statistics experts decided to close the trial early.
They found it wasn’t acceptable to continue with the trial because
- There was no benefit in having intensive treatments compared to standard treatment
- People in the high dose treatment group had more severe side effects, such as fever and infections, compared with the standard treatment group
- RCHOP had replaced CHOP as standard treatment for this patient group
We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Professor David Linch
Cancer Research UK
Haematology Trials Group
NIHR Clinical Research Network: Cancer
This is Cancer Research UK trial number CRUK/02/008.